ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 8.9% on Tuesday . The stock traded as high as $2.98 and last traded at $2.95. Approximately 1,898,971 shares were traded during mid-day trading, an increase of 26% from the average daily volume of 1,504,337 shares. The stock had previously closed at $2.71.

ZIOP has been the subject of several research analyst reports. Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Friday, December 7th. BidaskClub upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. HC Wainwright set a $6.00 price objective on ZIOPHARM Oncology and gave the stock a “buy” rating in a report on Tuesday, November 13th. Finally, Raymond James upgraded ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $4.92.

Get ZIOPHARM Oncology alerts:

The company has a market cap of $385.85 million, a P/E ratio of -5.57 and a beta of 2.44.

A number of hedge funds have recently bought and sold shares of ZIOP. MSD Partners L.P. increased its position in ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock valued at $20,544,000 after buying an additional 7,575,758 shares in the last quarter. FMR LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter valued at approximately $1,647,000. Ibex Investors LLC bought a new position in ZIOPHARM Oncology during the 4th quarter valued at approximately $755,000. Bank of America Corp DE increased its position in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares in the last quarter. Finally, Old West Investment Management LLC increased its position in ZIOPHARM Oncology by 784.7% during the 4th quarter. Old West Investment Management LLC now owns 223,319 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 198,077 shares in the last quarter. 40.12% of the stock is owned by institutional investors.

WARNING: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4199573/ziopharm-oncology-ziop-stock-price-up-8-9.html.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Recommended Story: Dollar Cost Averaging